"Shantha expects a turnover of Rs.500 crore a year from Shan5 in the next few years and plans to ramp up the production facility accordingly. Iyer put the worldwide demand for pediatric pentavalent vaccines at 200 million doses a year."
Hyderabad, May 5 - Shan5, a paediatric pentavalent or five-in-one vaccine developed by Hyderabad-based Shantha Biotechnics, an arm of Sanofi Pasteur, the vaccines division of French pharmaceutical company Sanofi, has regained prequalification status from the World Health Organisation -.

After four years of disqualification, the vaccine, which offers protection to children from diphtheria, tetanus, pertussis, Hib and hepatitis B, is back on the approved list of the WHO.

Harish Iyer, managing director and CEO of Shantha Biotechnics, announced at a news conference here Monday that the company will now bid for supply orders from different parts of the world.

The vaccine, the first to be jointly developed by Shantha and its parent company Sanofi, will also eligible for some funding from the UN's recognised agencies.

The WHO had earlier given prequalification status to the vaccine developed by Shantha and the company had sold 18 million doses between 2008 and 2010. However, the WHO later withdrew the status.

Shantha's founder and non-executive chairman K.I. Varaprasad Reddy said the vaccine lost the status due to sedimentation issue.

Sanofi, which acquired Shantha in 2009, spent around Rs.1,000 crore on upgradation of the facility and conduct the clinical trials from scratch to develop a better product and regain the prequalification status.

The company conducted clinical trials on 1,100 infants at 11 medical school study centres across India to meet global standards of quality, safety and efficacy.

In March this year, the firm received approval from the Drug Controller General of India to market the vaccine in the country.

Shantha expects a turnover of Rs.500 crore a year from Shan5 in the next few years and plans to ramp up the production facility accordingly. Iyer put the worldwide demand for pediatric pentavalent vaccines at 200 million doses a year.

The three-dose vaccine can be given starting from six weeks with a gap of four weeks up to 14 weeks of age.


comments powered by Disqus
Read more on:
 INDIA (136901 views)
 HYDERABAD (60597 views)
 HEALTH (17591 views)
 500 (8141 views)
 THE WHO (7361 views)
 MANAGING DIRECTOR (5031 views)
 BIOTECH (4191 views)
 ORDE (4061 views)
 11 (3961 views)
 EGAIN (3821 views)
 DIPHTHERIA (699 views)
 MEDICAL SCHOOL (681 views)
 

PERMALINK

http://www.nerve.in/news:2535002371955
You can quote the permanent link above for a direct link to the story. We do not archive or expire our news stories.


STORY OPTIONS
  Email this story to a friend
  XML feed for India


 
COPYRIGHTS INFORMATION
All rights reserved for news content. Reproduction, storage or redistribution of Nerve content and articles in any medium is strictly prohibited.
Contact Nerve Staff for any feedback, corrections and omissions in news stories.
 

All rights reserved for the news content. Reproduction, storage or redistribution of Nerve content and articles in any medium is strictly prohibited.